drugset / Trial / NCT07235930
Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
A randomized, multicenter, Phase III trial evaluating the efficacy and safety of first-line Sequential AG-mFOLFOX chemotherapy combined with Serplulimab and Bevacizumab versus AG chemotherapy alone in advanced pancreatic cancer. The primary endpoint is Overall Survival (OS). Approximately 292 patients will be enrolled in China.
Timeline
- Start
- 2025-11-15
- Primary completion
- 2029-07-01
- Completion
- 2029-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 400 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1 g | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Subject | Serplulimab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |